Detalles de la búsqueda
1.
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
Blood
; 137(19): 2646-2656, 2021 05 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33512419
2.
Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death.
Cancer
; 123(13): 2467-2471, 2017 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28192602
3.
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Blood
; 119(4): 940-8, 2012 Jan 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-22160383
4.
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
Haematologica
; 99(1): 148-54, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23996482
5.
Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.
Lancet
; 366(9501): 1935-44, 2005 Dec 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-16325695
6.
Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group.
J Clin Oncol
; 31(22): 2819-24, 2013 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23796987
7.
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
J Clin Oncol
; 30(24): 2946-55, 2012 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-22802322
Resultados
1 -
7
de 7
1
Próxima >
>>